SCHEMBL969771

SCHEMBL969771

O=C(CN1CCc2c([nH]c3cnncc23)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.52
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
GPX4 P36969 1/20 0.36
GRIN2B Q13224 1/20 0.36
NPC1 O15118 1/20 0.36
PRMT5 O14744 3/20 0.35
WDR77 Q9BQA1 3/20 0.35
HRH3 Q9Y5N1 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967154 0.87 PARP1 (0.52) PARP1KDM4EALDH1A1HPGDGPX4
SCHEMBL969260 0.87 PARP1 (0.52) PARP1KDM4EALDH1A1HPGDGPX4
SCHEMBL13985932 0.85 PARP1 (0.49) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL970324 0.84 ALDH1A1 (0.64) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL968745 0.84 PARP1 (0.47) PARP1KDM4EALDH1A1HPGDNPC1
SCHEMBL969089 0.84 PARP1 (0.65) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL968877 0.83 PARP1 (0.47) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL968434 0.83 ALDH1A1 (0.64) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL967118 0.82 ALDH1A1 (0.63) PARP1KDM4EALDH1A1HPGDCASP1
SCHEMBL969411 0.82 PARP1 (0.48) PARP1KDM4EALDH1A1HPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885KDM4E 3037/4885ALDH1A1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.